# First in Man Study of the DREAMS 2nd Generation Drug Eluting Absorbable Metal Scaffold (BIOSOLVE-II)

Study · id `cardio:ct-nct01960504` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01960504](<https://clinicaltrials.gov/study/NCT01960504>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01960504

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is unknown. It enrolled 123 participants.

## Technical summary

Registry record NCT01960504. Allocation not applicable; no masking; primary purpose treatment. Start 2013-10 (actual); primary completion 2015-08 (actual). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 123 participants (enrolled count; ClinicalTrials.gov record NCT01960504, source copy `cardio:ctgov-nct01960504-2020-01-18`, retrieved 2026-10-26)
- Started: 2013-10 (actual) (ClinicalTrials.gov record NCT01960504, source copy `cardio:ctgov-nct01960504-2020-01-18`, retrieved 2026-10-26)
- Primary completion: 2015-08 (actual) (ClinicalTrials.gov record NCT01960504, source copy `cardio:ctgov-nct01960504-2020-01-18`, retrieved 2026-10-26)
- Completion: 2020-05 (anticipated) (ClinicalTrials.gov record NCT01960504, source copy `cardio:ctgov-nct01960504-2020-01-18`, retrieved 2026-10-26)
- Countries: Belgium; Brazil; Denmark; Germany; Netherlands; Singapore; Spain; Switzerland (ClinicalTrials.gov record NCT01960504, source copy `cardio:ctgov-nct01960504-2020-01-18`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01960504-2020-01-18`, retrieved 2026-10-26)

## The registry's words

- Brief title: First in Man Study of the DREAMS 2nd Generation Drug Eluting Absorbable Metal Scaffold (BIOSOLVE-II)
- Acronym: BIOSOLVE-II
- Condition: Coronary Artery Disease
- Condition: Coronary Artery Stenosis
- Intervention (Device): Percutaneous Coronary Intervention (DREAMS) stenting
- Lead sponsor: Biotronik AG
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Atherosclerosis (`cardio:atherosclerosis`)
- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry lists this organization as the lead sponsor: Biotronik AG (`cardio:org-biotronik-ag`)

## Provenance

Content hash: 8203ae27c986d5461b46a455e7c079f1f0a2e425ea706a2e25f3862e76a94328
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
